[4-(3-furan-3-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-dimethyl-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-(3-furan-3-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-dimethyl-amine
• 英文别名: 4-[3-(furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylaniline
• 化学式: C₁₉H₁₇N₃O
• 分子量: 303.363
• InChiKey: XTAPQHYDIHPPQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  45.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  [4-(1-benzenesulfonyl-3-furan-3-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-dimethyl-amine 在 sodium hydroxide 、 水 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以82%的产率得到[4-(3-furan-3-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-dimethyl-amine
  参考文献：
  名称：

  [EN] JNK INHIBITORS
  [FR] INHIBITEURS DES JUN-KINASES (JNK)

  摘要：

  公开号：

  WO2004078756A3

文献信息

• Jnk inhibitors
  申请人：Graczyk Piotr

  公开号：US20060270646A1

  公开（公告）日：2006-11-30

  The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

  本发明提供了式（I）的新型化合物，并且它们可用于抑制c-Jun N末端激酶。本发明还提供了这些化合物在医学上的应用，特别是在预防和/或治疗与凋亡和/或炎症相关的神经退行性疾病中的应用。
• JNK INHIBITORS
  申请人：GRACZYK Piotr

  公开号：US20090215771A1

  公开（公告）日：2009-08-27

  The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

  本发明提供了式I的新化合物，以及它们在抑制c-Jun N-末端激酶中的应用。本发明还提供了这些化合物在医学中的应用，特别是在预防和/或治疗与细胞凋亡和/或炎症有关的神经退行性疾病方面的应用。
• JNK inhibitors
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2295433A2

  公开（公告）日：2011-03-16

  The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

  本发明提供了式(I)的新型化合物及其在抑制c-Jun N-末端激酶中的用途。本发明进一步提供了这些化合物在医学中的用途，特别是在预防和/或治疗与细胞凋亡和/或炎症有关的神经退行性疾病中的用途。
• Therapeutic Methods For Type I Diabetes
  申请人：Davis Roger J.

  公开号：US20120208846A1

  公开（公告）日：2012-08-16

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• US7432375B2
  申请人：——

  公开号：US7432375B2

  公开（公告）日：2008-10-07